According to the results of our single-cell transcriptomic analysis and flow cytometry of tumor-infiltrating immune cells, OV-mOX40L treatment decreased Foxp3+ Tregs, activated CD4+ and CD8+ T cells, and resulted in less exhausted CTLs. This evidence concerns the gene CD8A and neoplasm.